Jade Biosciences, Inc. (JBIO)
Nasdaq: JBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Who owns Jade Biosciences, Inc.
As filed with the SECHolders of 5% or more
8
Fairmount Funds Management LLC holds 20% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Jun 9, 2026 says.
Directors and officers
14
report now, of 35 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Fairmount Funds Management LLC
SCHEDULE 13D/A · filed Jun 9, 2026 · Common Stock, $0.0001 par value per share · 20% in Oct 8, 2025
Fmr LLC
SCHEDULE 13G · filed Jun 6, 2025 · COMMON STOCK
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Jul 8, 2026 · Common Stock · 6.3% in May 15, 2026
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value · 9.9% in Feb 17, 2026
RA Capital Management, L.P.
SCHEDULE 13G · filed Oct 16, 2025 · Common Stock, $0.0001 par value per share · 4.1% in Apr 30, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock · 4.7% in Apr 27, 2026
Paradigm BioCapital Advisors LP
SCHEDULE 13G · filed Jul 17, 2026 · Common Stock, $0.0001 par value per share
Bellevue Group AG
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 6.8% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Jan 30, 2026 · Common Stock · reported falling below 5%, from 5.6% in Jul 29, 2025
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 4.2% in Aug 14, 2025
Sofinnova Venture Partners X, L.P. ("SVP X")
SCHEDULE 13D/A · filed Mar 5, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
TCG Crossover GP I, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Atlas Venture Fund XII, L.P.
SCHEDULE 13D/A · filed Apr 30, 2025 · Common Stock · reported falling below 5%
Deep Track Capital, LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.99% in Nov 14, 2025
What JBIO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Aerovate Therapeutics, Inc.
An entity · consolidated entity · owns, named in the 10-K filed Mar 6, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 6, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.